Search Results 81-90 of 18147 for alopecia

  1. A Study Of IBI363 In Subjects With Advanced Solid Malignancies - Mayo Clinic

    0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to investigator' discretion) or baseline prior to the first ...

  2. Chemotherapy for breast cancer - Mayo Clinic

    Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in breast cancer patients: The HOPE study. Frontiers in Oncology ...

  3. Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer - Mayo Clinic

    ... alopecia - Patients who are receiving any other investigational agents - Patients with uncontrolled intercurrent illness - Patients who cannot discontinue ...

  4. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

    ... alopecia). Patient is currently receiving or has received systemic ... Exception to this criterion: patients with any grade of alopecia are allowed to enter the ...

  5. Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors - Mayo Clinic

    ... alopecia, bone marrow and organ functions); Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the ...

  6. A Study of a Personalized Neoantigen Cancer Vaccine - Mayo Clinic

    ... alopecia, and hypothyroidism that is controlled with hormone replacement therapy). Active, known, or suspected autoimmune disease. Note: Patients with type ...

  7. A Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma - Mayo Clinic

    or greater at the time of starting study treatment except for alopecia. - History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen

  8. A Study to Evaluate Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer - Mayo Clinic

    Exceptions: Residual alopecia and Grade 2 peripheral neuropathy are allowed. Concurrent use of strong and moderate inducers and/or strong inhibitors of ...

  9. Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working - Mayo Clinic

    (which must be ≤ grade 2), alopecia and/or endocrinopathies related to prior immunotherapy which are controlled with hormone replacement. - Patients must ...

  10. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2 ...